MLTX · Healthcare
MOONLAKE IMMUNOTHERAPEUTICS
Smart-money confidence
· 1 of 3 sources firing
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
32
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
◆ Next steps
Interested in MOONLAKE IMMUNOTHERAPEUTICS? Here's what to do with it.
◇
Compare with other stocks
Sort 7,111 stocks by confidence, holders, or Congress signal
◈
Backtest the strategy
See how the model has done historically before you commit real money
✉
Get the weekly digest
One email on Sunday · what changed in the model this week
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$1.7B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqCM
About MOONLAKE IMMUNOTHERAPEUTICS
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Who's behind the signal
Every informed buyer we can see on MLTX, across all three feeds.
Hedge funds · 6
D.E. Shaw & Co
New position
Tudor Investment (Paul Tudor Jones)
New position
AQR Capital Management
New position
Point72 (Steve Cohen)
Increased +7783%
Millennium Management (Englander)
Increased +800%
Citadel Advisors
Increased +672%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
MOONLAKE IMMUNOTHERAPEUTICS isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
3
New positions
3
Increasing
0
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.2×
% of portfolio
0.0%
Position change
NEW
0.0% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of AQR Capital Management's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
+7783%
0.0% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+800%
0.0% of Millennium Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+672%
0.0% of Citadel Advisors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to MOONLAKE IMMUNOTHERAPEUTICS
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell MOONLAKE IMMUNOTHERAPEUTICS or any security.
Get the Weekly Update
Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime